VITRAKVI (larotrectinib)
TherapyBayer
VITRAKVI (larotrectinib) from Bayer is a tumor-agnostic therapy used in NTRK fusion–positive solid tumors.
Approvals
2
Indications
1
Biomarkers
3
Mapped tests
2
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and VITRAKVI. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where VITRAKVI is tied to a specific indication and biomarker definition.
No indication-specific companion diagnostic approvals are currently mapped for this therapy.
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for VITRAKVI.
| Level | Biomarker criteria | Notes | |
|---|---|---|---|
| Solid Tumors | NTRK1
|
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering VITRAKVI for eligible patients.
Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
TruSight Oncology Comprehensive
Illumina, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →